RedHill Biopharma (RDHL) Profit After Tax (2012 - 2023)

RedHill Biopharma (RDHL) has reported Profit After Tax for 12 consecutive years, with $101.2 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Profit After Tax rose 764.51% year-over-year to $101.2 million in Q2 2023; TTM through Jun 2023 was $90.4 million, a 15.94% increase from a year earlier, with the FY2025 full-year figure at -$8.1 million, down 2344.44% from the prior year.
• Profit After Tax was $101.2 million for Q2 2023 at RedHill Biopharma, up from -$50.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $101.2 million in Q2 2023 and troughed at -$50.2 million in Q1 2023.
• A 5-year average of $18.8 million and a median of $17.9 million in 2020 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 764.51% in 2023, down 344.74% in 2023.
• Over 5 years, Profit After Tax stood at $11.7 million in 2019, then soared by 108.12% to $24.3 million in 2020, then advanced by 0.17% to $24.4 million in 2021, then slumped by 84.7% to $3.7 million in 2022, then jumped by 2615.02% to $101.2 million in 2023.
• The last three Profit After Tax figures came in at $101.2 million (Q2 2023), -$50.2 million (Q1 2023), and $3.7 million (Q4 2022), per Business Quant data.